

ASX Announcement

NEW DATA FROM IMMUTEPT'S EFTI TO BE PRESENTED AT ESMO

SYDNEY, AUSTRALIA – 26 August 2020 – [Immutep Limited](#) (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, pleased to announce new data is scheduled to be presented in four poster presentations at the ESMO Virtual Congress 2020 which is being held from 19 to 21 September 2020, Central European Summer Time (CEST).

The new data will be presented from Immutep's phase II TACTI-002 and the investigator-initiated phase I clinical trial, INSIGHT which includes INSIGHT-004. All four poster presentations relate to the Company's lead product candidate, eftilagimod alpha ("efti" or "IMP321"). Immutep will announce the data to the market and make the posters available on its website.

ESMO is Europe's most prestigious oncology congress, attracting more than 29,000 industry participants from 137 countries last year. This year it is being held in a virtual format due to COVID-19.

Poster presentations:

Title: *Initial results from a Phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients*

Date: 17 September 2020, CEST

Presenter: Dr Martin Forster, University College London Hospital, London, United Kingdom

Title: *Initial results from a Phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected 1st line metastatic non-small cell lung carcinoma*

Date: 17 September 2020, CEST

Presenter: Dr Margarita Majem, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Title: *Safety data from stratum D of the phase I INSIGHT platform trial evaluating feasibility of IMP321 (LAG-3lg protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumor entities*

Date: 17 September 2020 CEST

Presenter: Dr Thorsten O. Goetze, Krankenhaus Nordwest, University Cancer Center, Frankfurt am Main, Germany

For personal use only

Title: *The phase I INSIGHT platform trial: Strata A and B evaluating feasibility of intratumoral and intraperitoneal IMP321 (soluble LAG-3 protein, eftilagimod alpha) in advanced solid tumors*

Date: 17 September 2020 CEST

Presenter: Prof Salah-Eddin Al-Batran, Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH in Frankfurt, Germany (IKF)

About TACTI-002

TACTI-002 is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada). It is evaluating the combination of efti with MSD’s KEYTRUDA[®] (or pembrolizumab, an anti-PD-1 therapy) in up to 109 patients.

About INSIGHT and INSIGHT-004

INSIGHT is a phase I investigator-initiated study being conducted by Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH in Frankfurt, Germany (IKF). It is evaluating efti as a monotherapy in 12 patients with advanced solid malignancies.

INSIGHT-004 is the fourth arm (stratum D) of the INSIGHT trial and is being conducted under Immutep’s collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc. It is evaluating the safety, tolerability and recommended Phase II dose of efti when given in combination with avelumab in 12 patients with advanced solid malignancies.

About Immutep

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 immunotherapies for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM) and the NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3Ig fusion protein which is a first-in-class antigen presenting cell (APC) activator. Efti is currently in a Phase IIb clinical trial known as AIPAC which is evaluating efti in combination with chemotherapy for the treatment of metastatic breast cancer (clinicaltrials.gov identifier NCT02614833); a Phase II clinical trial being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada) referred to as TACTI-002 to evaluate a combination of efti with KEYTRUDA[®] (pembrolizumab) in several different solid tumours (clinicaltrials.gov identifier NCT03625323); a Phase I clinical trial being conducted in collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc. referred to as INSIGHT-004 to evaluate a combination of efti with avelumab (clinical trials.gov identifier NCT03252938); and a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT02676869).

Further information can be found on the Company's website www.immutep.com or by contacting:

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:

Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; tim@lifesciadvisors.com

This announcement was authorised for release by the CEO of Immutep Limited.

For personal use only